Dr. Reddy's Recalls Ranitidine Medications in U.S.
October 23 2019 - 1:24PM
Dow Jones News
By Michael Dabaie
Dr. Reddy's Laboratories Ltd. (RDY) said it initiated a
voluntary recall on October 1 of all of its ranitidine medications
sold in U.S.
The pharmaceutical company said the recall was due to confirmed
contamination with N-Nitrosodimethylamine, or NDMA, above levels
established by the FDA.
The U.S Food and Drug Administration in September said it
learned some ranitidine medicines contain NDMA, a nitrosamine
impurity.
Dr. Reddy's said it hasn't received any reports of adverse
events related to the recall of its ranitidine products. The recall
includes all quantities in the U.S. that are within expiry, the
company said.
Dr. Reddy's ADRs were up 3% to $39.91 in afternoon trading.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 23, 2019 13:09 ET (17:09 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Sep 2023 to Sep 2024
